Early Cascade Screening and Lipid-Lowering Therapy in Childhood: Challenges in the Management of Familial Hypercholesterolemia

Q: What is the clinical evidence from this study?

Study design: Case Report. Population: Familial Hypercholesterolemia (n=1). Intervention: Atorvastatin. Primary outcome: Low-density lipoprotein cholesterol (LDL-C).

Q: What does this research mean for the field?

Early cascade screening and initiation of lipid-lowering therapy substantially reduces LDL-C in young children with familial hypercholesterolemia, although treatment intensification is often needed to achieve target levels. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

Juliana Zanotti; Eduardo Tomaz Quartero Martim; Renato Jorge Alves

doi:10.36660/ijcs.20260095

January 1, 2026International Journal of Cardiovascular SciencesOpen Access

Early Cascade Screening and Lipid-Lowering Therapy in Childhood: Challenges in the Management of Familial Hypercholesterolemia

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Early diagnosis and management of Familial Hypercholesterolemia in children through cascade screening and lipid-lowering therapy is critical to reduce long-term cardiovascular risk.

Key Points

To describe the role of cascade screening and early individualized lipid-lowering therapy in a young pediatric patient diagnosed with familial hypercholesterolemia.
Conducted clinical evaluation and cascade family screening in a five-year-old child presenting with a family history of severe hypercholesterolemia and premature cardiovascular disease in Brazil.
Initiated lipid-lowering therapy before the standard guideline-recommended age of 8 years following the detection of subclinical cardiovascular involvement via echocardiography.
Echocardiogram identified subclinical atherosclerosis manifesting as a calcified, hyperechoic nodular lesion measuring 3 mm on the caudal surface of the aortic arch.
Despite substantial reductions in low-density lipoprotein cholesterol following therapy initiation, lipid levels remained above therapeutic targets of < 100 mg/dL for intermediate risk and < 70 mg/dL for high cardiovascular risk.

Study Design

Type

Case Report (n=1)

Structured PICO

P

Population

1 eight-year-old male with possible familial hypercholesterolemia and subclinical atherosclerosis, identified via cascade screening and treated with statin therapy.

I

Intervention

Atorvastatin 10 mg/day started at age 5, increased to 20 mg/day after 12 months.

O

Outcome

Reduction in total cholesterol and LDL-C levelssurrogate

Early cascade screening and off-label early initiation of statin therapy at age 5 in a child with subclinical atherosclerosis effectively lowered LDL-C, highlighting the need for individualized, proactive management of familial hypercholesterolemia.

Limitations

Unavailability of genetic testing at the institution
Reliance on the Dutch Lipid Clinic Network Score (DLCNS), which may be insufficient for pediatric diagnosis
unavailability of genetic testing at the institution

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Supports cascade screening for familial hypercholesterolemia in children; leaves open optimal regimens to reach LDL-C targets.

Abstract

This case highlights the importance of cascade screening for the early diagnosis of Familial Hypercholesterolemia (FH) in children.Early identification at the age of five enabled the timely initiation of lipid-lowering therapy and underscored the need for individualized treatment based on atherosclerotic risk.Despite a substantial reduction in LDL-C levels, the patient remained above recommended therapeutic targets, emphasizing the need for ongoing monitoring and treatment intensification.The detection of subclinical atherosclerosis further reinforces the importance of continuous cardiovascular surveillance.A comprehensive management strategy combining cascade screening, family-based risk assessment, and early intervention is essential to reduce long-term cardiovascular risk and improve clinical outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zanotti et al. (2026) conducted a case report in Familial Hypercholesterolemia (n=1). Atorvastatin was evaluated on Low-density lipoprotein cholesterol (LDL-C).

synapsesocial.com/papers/6ad0fce415427f6a84040379 https://doi.org/10.36660/ijcs.20260095

View Full Paper

Ask AI

Bookmark

Share

Early Cascade Screening and Lipid-Lowering Therapy in Childhood: Challenges in the Management of Familial Hypercholesterolemia

Key Points

Study Design

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Early Cascade Screening and Lipid-Lowering Therapy in Childhood: Challenges in the Management of Familial Hypercholesterolemia

Key Points

Study Design

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading